Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Leukemia
Mehmet Kemal SamurNikhil C Munshi

Abstract

Although long intergenic non-coding RNAs (lincRNA) role in various cancers is described, their significance in Multiple Myeloma (MM) remains poorly defined. Here we have studied the lincRNA profile and their clinical impact in MM. We performed RNA-seq on MM cells from 308 newly diagnosed and uniformly treated patients, 16 normal plasma cells and utilized RNA-seq data from 532 newly diagnosed patients from CoMMpass study to analyze for lincRNAs. We observed 869 differentially expressed lincRNAs in MM compared to normal plasma cells. We identified 14 lincRNAs associated with PFS and calculated a risk score to stratify patients. The median PFS between high vs low-risk groups was 17 months vs not-reached (NR); and OS 30 months vs NR, respectively (p < 0.0001 for both). In the independent validation dataset between high and low-risk groups, PFS was 27 vs 42 months (HR 2.06 [1.44-2.96]; p < 0.0005); and 4-year OS 62% vs 86% (HR 2.76 [1.51-5.05]; p < 0.0005) confirming significant clinical relevance of lincRNA in MM. Importantly, lincRNA signature was able to further identify patients with significant differential outcomes within each low and high-risk categories identified using standard risk categorization including cytogenetic/FISH...Continue Reading

References

Mar 4, 2010·Genome Biology·Mark D Robinson, Alicia Oshlack
Feb 9, 2012·International Journal of Molecular Sciences·Ruth ZarateJesús Garcia-Foncillas
Jun 23, 2012·Leukemia·R KuiperP Sonneveld
Sep 8, 2012·Genome Research·Jennifer HarrowTim J Hubbard
Feb 4, 2014·Genome Biology·Charity W LawGordon K Smyth
Apr 30, 2014·Nature Reviews. Genetics·Kevin V Morris, John S Mattick
Jan 22, 2015·Nucleic Acids Research·Matthew E RitchieGordon K Smyth
Nov 6, 2015·Nature Medicine·Maite Huarte
Jan 16, 2016·Blood Cancer Journal·M FulcinitiN C Munshi
Jun 9, 2016·The New England Journal of Medicine·Joshua T Mendell
Mar 7, 2017·Nature Methods·Rob PatroCarl Kingsford
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study

❮ Previous
Next ❯

Citations

Oct 30, 2018·Journal of Cellular Physiology·Qian YangShaoqing Ju
Feb 6, 2020·Cancers·Eugenio MorelliNicola Amodio
Apr 24, 2020·Journal of Cellular Physiology·Jingwen LiYu Hu
Jul 21, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mehmet Kemal SamurNikhil C Munshi
Aug 24, 2018·International Journal of Molecular Sciences·Mette DahlKirsten Grønbæk
Jan 27, 2019·Non-coding RNA·Romana ButovaRoman Hajek
Sep 13, 2020·Non-coding RNA·Lavinia RaimondiNicola Amodio
Jul 25, 2020·Haematologica·Annamaria Gulla, Kenneth C Anderson
Oct 16, 2020·Haematologica·Annamaria Gulla, Kenneth C Anderson
May 1, 2021·Cancers·Arantxa Carrasco-LeónXabier Agirre
May 7, 2021·The Application of Clinical Genetics·Hamza Hassan, Raphael Szalat
Aug 28, 2021·International Journal of Molecular Sciences·Muhammad Nabeel AsimSheraz Ahmed
Oct 10, 2021·Blood Cancer Journal·Srikanth TalluriNikhil C Munshi

❮ Previous
Next ❯

Methods Mentioned

BETA
RNAseq
ISS
Genotyping
RNA-seq

Clinical Trials Mentioned

NCT01191060

Software Mentioned

lincRNA
multtest
R
stepwise
Limma
My
Salmon

Related Concepts

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.